Diamyd is a biopharmaceutical company in the field of diabetes. Today the company's research and development concentrates on autoimmune diabetes and complications related to diabetes. The company's vision is to one day be able to prevent and cure the autoimmune form of diabetes. The goal is to be able to treat children, adolescents and adults with diabetes and to vaccinate in order to prevent the disease from breaking out. After several years of successful research and good results we now know that the diabetes vaccine Diamyd
® significantly slows the disease process, which gives hope to diabetes patients.
- Vision: Prevent and cure the autoimmune form of diabetes
- Goal: Treat children, adolescents and adults with diabetes and to vaccinate in order to prevent the disease from breaking out
Business Model
Diamyd Medical is run as a virtual company, with low costs and an efficient organization. Over the last 10 years the company has conducted four clinical studies of the Diamyd
® vaccine and started two large global Phase III studies at very low cost. This successful cost-effective concept is based on the powerful combination of a strong entrepreneurial spirit and determined management well-versed in business logic. Diamyd Medical is listed on the Nasdaq OMX Nordic Market Small Cap list, as well as the OTCQX in the US. Research, which will result in proprietary products, provides a stable foundation for building a Small Pharma Company in the diabetes field.
Product strategy
It is Diamyd's intention to gain marketing approval for Diamyd
® for type 1 diabetes under its own direction, and to conduct the marketing and sales of the product in some key markets. At onset of type 1 diabetes, patients are typically treated by paediatric endocrinologists specializing in juvenile diabetes, a very limited group of physicians working primarily at specialty clinics and university hospitals. The limited number of relevant physicians means that a market launch could be carried out by a relatively small and cost-effective sales organization.
Diamyd plans to out-license Diamyd
® for LADA on a global basis. Unlike type 1 diabetes patients, LADA patients are predominantly treated by general practitioners, which significantly broadens the market and makes it more challenging from a marketing perspective.
The strategy for the Nerve Targeting Drug Delivery System (NTDDS) platform is to develop drugs related to diabetes complications and to out-license them after Phase II clinical trials. Additionally, the company plans to out-license the use of the NTDDS technology for diseases other than diabetes, such as cancer.